The Albers Laboratory uses the olfactory system of mice and humans to explore early pathologic events of neurodegeneration.
Research Labs at the Healey Center
Borrowing from successes in cancer drug development, the Healey Center and NEALS faculty are leading the first ALS Platform Trial.
PREVENT ALS is an initiative with big goals: Stopping ALS in its tracks – before it begins.
The NEALS Biorepository/ALS Living Library at Mass General stores and shares over 100,000 plasma, serum, cerebro-spinal fluid and whole blood samples from people with ALS and controls for use by the ALS research community.
Clotilde Lagier-Tourenne performs patient-oriented research to understand the molecular mechanisms driving neurodegeneration in Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD) and to develop therapeutic strategies.
The MassGeneral Institute for Neurodegenerative Disease (MIND) is a research center for Alzheimer’s, ALS (Lou Gehrig’s), Huntington’s, Parkinson’s and other neurodegenerative diseases.
The Neurological Clinical Research Institute (NCRI) at Mass General is an academic research organization that designs, develops, facilitates and conducts multicenter clinical trials in neurological diseases.
Our laboratory focuses on identifying common mechanisms that cause neurodegenerative disease in order to identify novel therapeutic targets.
Transforming Medicine Through Innovation
Research at Massachusetts General Hospital integrates the full spectrum of "bench to bedside" discovery. Laboratory scientists work collaboratively with clinicians to make discoveries and turn them into treatments, diagnostics and devices that improve our quality of life.